Research Article Details
| Article ID: | A27647 |
| PMID: | 17766001 |
| Source: | Diabetes Res Clin Pract |
| Title: | Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance. |
| Abstract: | OBJECTIVE: The aim of our study was to examine the changes in hypertransaminasemia after weight reduction in obese patients with and without nonalcoholic fatty liver disease (NAFLD) and the relation with insulin resistance. RESEARCH METHODS: A population of 142 obesity nondiabetic was treated with a hypocaloric diet (1520 kcal) during 3 months. Patients were classified as group I (control, n=112) when serum (alanine aminotransferase) ALT activity was normal or group II (NAFLD, n=30) when serum ALT activity was greater than the upper limit of normal reference laboratory (>or=43 UI/L). RESULTS: In control group, body mass index (BMI) (35.3+/-5.6 vs. 33.5+/-5.5: p<0.05), weight (89.6+/-17.2 kg vs. 85.6+/-16.5 kg: p<0.05) and insulin (15+/-7.9 mUI/L vs. 13.1+/-7.4 mUI/L: p<0.05) levels decreased. In NAFLD group, BMI (37.1+/-4.2 vs. 35.1+/-4.6: p<0.05), weight (101+/-22 kg vs. 96.4+/-11.6 kg: p<0.05), insulin (26.8+/-8.9 mUI/L vs. 12.7+/-8.4 mUI/L: p<0.05) and HOMA (3.1+/-1.6 vs. 1.9+/-1.7: p<0.05) decreased. Liver function improved in both groups (ALT; group I 19.9+/-4.6 UI/L vs. 18.3+/-3.9 UI/L: p<0.05 and group II 37.8+/-4.2 UI/L vs. 27.1+/-7.8 UI/L: p<0.05), (aspartate aminotransferase activity, AST) group I 22.1+/-8.2 UI/L vs. 19.9+/-7.1 UI/L: p<0.05 and group II 73.3+/-11.3 UI/L vs. 38.1+/-11.6UI/L: p<0.05). CONCLUSION: We showed that weight reduction secondary to a hypocaloric diet were associated with improvement in hypertransaminasemia and insulin resistance in NAFLD patients. |
| DOI: | 10.1016/j.diabres.2007.07.015 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |